BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-targeted therapies are highly effective at preventing breast cancer recurrence but are associated with cardiotoxicity in some patients, and minimal data are available regarding racial disparities in the incidence of this toxicity. The authors conducted a retrospective study to analyze the association of black or white race with treatment-induced cardiotoxicity and incomplete therapy among patients with HER2-positive early breast cancer. METHODS: Women with HER2-positive, stage I through III breast cancer who initiated (neo)adjuvant HER2-targeted therapy (trastuzumab with or without pertuzumab) from January 2005 to March 2015 at the authors' institution were eligible. We analyzed differences in the incidence of cardiotoxicity (a decline in the left ventricular ejection fraction to <50% AND an absolute drop in the left ventricular ejection fraction of 10% from baseline) and incomplete therapy (<52 weeks of HER2-targeted therapy) between black and white women in univariate and multivariable analyses. RESULTS: The authors identified 59 black patients and 157 white patients who had a median follow-up 5.2 years. The median patient age was 53 years and was similar for black and white patients. The 1-year cardiotoxicity incidence was 12% overall (95% confidence interval [CI], 7%-16%), 24% in black women (95% CI, 12%-34%), and 7% in white women (95% CI, 3%-11%). Black patients had a significantly greater probability of incomplete therapy compared with white patients (odds ratio, 4.61; 95% CI, 1.70-13.07; P 5 .002). High correlation was observed between a cardiotoxicity event and incomplete therapy (96% concordance). CONCLUSIONS: Black patients have a higher rate of cardiotoxicity and resultant incomplete adjuvant HER2-targeted therapy than white patients. This patient population may benefit from enhanced cardiac surveillance, cardioprotective strategies, and early referral to cardiology when appropriate.
INTRODUCTION
Human epidermal growth factor receptor-2 (HER2) is overexpressed or amplified in approximately 15% to 20% of invasive breast cancers. 1 Before the introduction of HER2-targeted therapies, such as the monoclonal antibody trastuzumab (Herceptin; Genentech, San Francisco, CA; and Roche, Basel, Switzerland), HER2-positive breast cancer was associated with a poor prognosis and a shorter overall survival (OS) than other breast cancer subtypes. 2, 3 Large multicenter, randomized controlled studies evaluating the addition of trastuzumab to standard chemotherapy regimens have demonstrated improvements of approximately 35% to 60% in disease-free survival and 23% to 33% in OS compared with chemotherapy alone. [4] [5] [6] [7] Studies evaluating the optimal duration of HER2-targeted therapy in this setting have supported the receipt of (neo)adjuvant trastuzumab for 1 year. 8, 9 In recent years, additional HER2-targeted therapies have been developed, including the HER2-dimerization inhibitor pertuzumab (Perjeta; Genentech; and Roche). 10 Although they generally are well tolerated, HER2-targeted therapies are associated with cardiotoxicity in some patients. The majority of these patients experience an asymptomatic decrease in the left ventricular ejection fraction (LVEF) that resolves with the discontinuation of therapy. 11 A 7-year follow-up analysis of the National Surgical Adjuvant
Breast and Bowel (NSABP) B-31 trial demonstrated cardiotoxicity rates of 4.0% in the trastuzumab arm and 1.3% in the non trastuzumab arm. 12 A Surveillance, Epidemiology, and End Results-Medicare database publication reported much higher rates of cardiotoxicity at 32.1% for trastuzumab without anthracycline and 41.9% for trastuzumab with anthracycline from a study of 45,537 patients who were not participating in clinical trials, although the definitions of cardiotoxicity in various studies differed. 13 Exposure to anthracycline therapy may be cardiotoxic and can also be a risk factor for the development of HER2-targeted therapy-mediated cardiotoxicity, although the mechanisms involved are distinct.
14 Anthracyclines cause type 1 cardiotoxicity associated with myocyte destruction through reactive oxygen species, whereas HER2-targeted therapies result in loss of contractility more similar to stunning or hibernation through the inhibition of signaling pathways. 15 In addition to prior anthracycline therapy, several clinical factors that predispose to this undesirable sequela have been identified, including older age, history of cardiac dysfunction, hypertension, and obesity. 16 However, the data on racial differences as a potential risk factor for the development of cardiotoxicity are extremely scarce. Of the larger prospective trials, only the HERA trial stratified data according to race, but that study enrolled only 20 black patients (<1%). 7 A large observational study reported a higher rate of grade 3 cardiac safety events in black patients (10.9%) versus white patients (7.9%) who were receiving trastuzumab for advanced breast cancer. 17 Two smaller retrospective studies also have demonstrated that black patients have a higher risk of developing cardiotoxicity related to the receipt of HER2-targeted therapies. 18, 19 We hypothesized that black patients with HER2-positive early breast cancer would have a higher probability of cardiotoxicity and an incomplete course of HER2-targeted therapy (incomplete therapy) than white patients. We designed a retrospective study to analyze the association of race with treatment-induced cardiotoxicity and receipt of incomplete therapy in patients with HER2-positive early breast cancer.
MATERIAL AND METHODS

Data Collection
We conducted a retrospective chart review of electronic medical records and paper records, where appropriate, of individuals with stage I through III, histologically confirmed, HER2-positive, invasive breast cancer who received neoadjuvant or adjuvant trastuzumab with or without pertuzumab between January 2005 and March 2015 at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Data were entered into an electronic research database and reviewed independently for completeness and accuracy before analysis. The project was reviewed and approved by the Johns Hopkins Institutional Review Board.
Data points comprised clinicopathologic features (ie, patient age and race; tumor stage, grade, size, and hormone-receptor/HER2 status), select comorbidities, and the receipt of antihypertensive medication ( Table 1) . We also collected information on local and systemic treatments received, including the duration of HER2-targeted therapy in weeks, the development of disease recurrence, and survival. Cardiovascular risk factors collected from the medical record included age, sex, known hyperlipidemia or diabetes, antihypertensive medication receipt, and smoking history.
20 HER2-positivity was defined as either: 1) overexpression of the protein characterized as 31 by immunohistochemistry or 2) amplification by at least 2.0 on fluorescent in situ hybridization. 21 Patients were included if they were initiated on chemotherapy regimens with the intent to administer at least 1 year of HER2-targeted therapy, if HER2-targeted therapy was initiated, and if at least 1 year of follow-up was available after the initiation of adjuvant therapy. The systemic chemotherapy regimens varied based on provider preference as well as patient tolerability and included variants of FEC-H (F-5 fluorouracil, E-epirubicin, C-cyclophosphamide, H-trastuzumab), AC-TH/AC-H (A-adriamycin, C-cyclophosphamide, T-paclitaxel, H-trastuzumab); and TCH/TCHP/TH/HP (T-Docetaxel, C-cyclophosphamide, H-trastuzumab, P-pertuzumab).
Exclusion criteria included male patients, those not designated as of black or white race, and those who had metastatic disease at diagnosis. In addition, patients who switched care to another health facility during HER2-targeted therapy, discontinued therapy secondary to psychosocial reasons, or had 2 or fewer determinations of LVEF during HER2-targeted therapy also were excluded.
Cardiac Evaluation
LVEF was measured either by multiple-gated acquisition scanning or by echocardiography. If a value was reported as a range of 6 5%, then the mean value was used. If a baseline LVEF was not available, then the LVEF after anthracycline-based therapy was used where applicable. Cardiotoxicity was defined as an LVEF decline to <50% AND an absolute drop in LVEF of 10% from baseline. 
Statistical Analysis
Demographics and clinicopathologic features were summarized by race using descriptive statistics. The clinical outcomes examined in this retrospective analysis included the cumulative incidence of cardiotoxicity at 1 year, completion of 1 year of HER2-targeted therapy (incomplete therapy was defined as less than 52 weeks of HER2-targeted therapy), and descriptive statistics of recurrencefree survival (RFS) and OS. No other event was deemed to be a competing event of cardiotoxicity. The cumulative incidence of cardiotoxicity at 1 year was estimated as a time-to-event outcome after the initial date of HER2-targeted therapy, in which the event was the occurrence of cardiotoxicity, and patients without cardiotoxicity were censored on the last follow-up date or the date of death. The correlation between incomplete therapy and cardiotoxicity was displayed using a contingency table, and the concordance rate was defined as a proportion of identical results between incomplete therapy and cardiotoxicity in the study cohort. OS was calculated as the time from initiation of HER2-targeted therapy to death from any cause, and patients who remained alive were censored at the time of last follow-up. RFS was calculated as the time from initiation of HER2-targeted therapy to the time of first documentation of a breast cancer recurrence at any site (ie, in-breast, axillary, chest wall, or distant metastases) or death from breast cancer, whichever occurred first. The cumulative incidence of cardiotoxicity and the probabilities of RFS and OS were estimated using the Kaplan-Meier method. 23, 24 Univariate and multivariable Cox regression analyses were performed to evaluate the prognostic impact of various clinicopathologic factors on the cumulative incidence of cardiotoxicity. Factors that were adjusted in the multivariable analyses for the effect of race on cardiotoxicity were selected based on published reports and investigators' clinical knowledge. In the current study, no hypotheses of RFS or OS were tested because of the small number of events. All statistical tests were 2-sided, P < .05 was considered the level of significance, and the analyses were carried out using the R statistical software package (version 3.3.1; R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
We identified 216 eligible patients (of whom 13 had received pertuzumab in addition to trastuzumab), including 59 black women (27.3%) and 157 white women (72.7%). The median patient age was 53 years (range, 26-82 years). At baseline, black women had a higher frequency of cardiovascular risk factors, such as diabetes, hypertension, hyperlipidemia, and smoking history, and were more likely to be prescribed more antihypertensive medications compared with white women (Table 1) . Black women presented with higher stage cancer at the time of diagnosis, were more likely to have hormone receptor-negative breast cancer, and were as likely to receive an anthracycline-based treatment regimen compared with white women.
The median time to cardiotoxicity event was 179 days (range, 70-448 days), and only 2 patients experienced cardiotoxicity later than 1 year after trastuzumab (at 377 and 448 days, respectively). The 1-year probability of a cardiotoxicity event was 0.12 overall (95% confidence interval [CI], 0.07-0.16), 0.24 in black women (95% CI, 0.12-0.34), and 0.07 in white women (95% CI, 0.03-0.11) (Fig. 1) . In univariate analysis, black women had a higher risk of cardiotoxicity compared with white women (hazard ratio, 3.22; 95% CI, 1.51-6.84; P 5 .002) (Supporting Table 1 ; see online supporting information). Multivariable Cox regression analysis also revealed that race was a significant predictor of cardiotoxicity (hazard ratio, 2.73; 95% CI, 1.24-6.01; P 5 .012) ( Table 2 ) when controlling for patient age, disease stage, the presence of cardiovascular risk factors, and prior receipt of anthracyclines.
The recommended course of HER2-directed therapy (1 year) was not completed in 22 patients (entire cohort, 10.2%; 5.7% of white patients and 22% of black patients) (Table 1) because of cardiotoxicity in 20 of 22 patients. Six of these patients (2 white, 4 black) were (Fig. 2) . DISCUSSION (Neo)adjuvant HER2-targeted therapy has become the standard of care for women with HER2-positive breast cancer. The majority of patients tolerate the therapy well; however, a few patients experience potentially serious side effects, such as cardiotoxicity, which can lead to treatment delays and early discontinuation of therapy. We hypothesized that an incomplete course of HER2-targeted therapy secondary to drug toxicity might be more prevalent in black patients. In the current study, we observed a cardiotoxicity rate at 1 year of 12.5% in the overall study population, consistent with the rates observed in the large prospective adjuvant trials (ranging from 5.7% to 18.0%). [4] [5] [6] [7] However, as hypothesized, black women in our study were more likely to develop cardiotoxicity in the setting of HER2-targeted therapy compared with white women (24% vs 7% at 1 year). A high correlation also was observed between the development of cardiotoxicity and incomplete therapy. These results complement findings from the observational RegistHER study (n 5 1001), which reported a higher rate of grade 3 cardiac safety events in black patients (10.9%) versus white patients (7.9%) who were receiving trastuzumab for advanced breast cancer. 17 However, our results are novel, because we investigated the association of race with both treatment-induced cardiotoxicity and incomplete therapy in an early breast cancer population.
The racial disparity we observed in rates of cardiotoxicity could relate to the finding that black women in this cohort had more cardiac comorbidities (diabetes, hypertension, hyperlipidemia, and smoking history). Clinical risk factors for the development of cardiotoxicity from HER2-targeted therapy have been identified previously and indeed include older age, prior exposure to or concurrent anthracycline use, high body mass index, lower baseline LVEF, and a history of hypertension. 16, 25 It is noteworthy that coronary artery disease, diabetes, and valvular dysfunction were not associated with the development of cardiotoxicity in the large prospective trials of adjuvant trastuzumab. Diabetes, however, has been identified as a risk factor in elderly patients who receive trastuzumab in the adjuvant or metastatic setting. 26 Genetic variations also may contribute to variable rates of cardiotoxicity from HER2-targeted therapy. A recent study of 140 women with breast cancer who were receiving trastuzumab revealed that the HER2 proline-to-alanine polymorphism at position 1170 (Pro1170 Ala) was associated with an increased risk of cardiotoxicity by 2.6-fold. 27 Other polymorphisms have also been identified, such as an isoleucine-to-valine polymorphism at position 655 (Ile655Val). 28 Those studies did not suggest that these polymorphisms were more prevalent in black patients. Additional research will be necessary to ascertain the link between genetic polymorphisms and the development of cardiotoxicity associated with HER2-targeted therapy.
It is unclear whether black patients who are receiving chemotherapy and HER2-targeted therapy should (14) 12 (86) undergo more intensive screening for cardiotoxicity. It is routine in clinical practice to monitor patients who are receiving these agents with serial LVEF evaluations, but this is not necessarily supported by strong evidence. 29 The American Society of Clinical Oncology and the American College of Cardiology are in the process of developing collaborative guidelines for patients who are receiving HER2-targeted therapy. Ideally, these recommendations can be supported by evidence from well designed clinical trials or large retrospective analyses and by considering closer surveillance for "at-risk" populations.
As the field of cardio-oncology is expanding, 30 research is ongoing to develop both preventive and therapeutic strategies for patients who are at risk for, or develop cardiotoxicity. Trastuzumab-induced cardiotoxicity has been related to activation of the renin-angiotensin system in a murine model, and it has been demonstrated that inhibition of the renin-angiotensin system with ACEIs, angiotensin receptor blockers (ARBs), and the renin inhibitor aliskerin potentially may prevent its development. 31 The Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) trial (n 5 120) demonstrated improved rates of cardiotoxicity with single-agent candesartan (an ARB), but not with metoprolol (a b blocker), in patients who were receiving adjuvant anthracycline-containing therapy with or without trastuzumab for early breast cancer. 32 Patients who were selected for that study were at low risk for the development of cardiotoxicity, and the follow-up period was short. The Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research (MANTICORE) trial evaluated whether perindopril (an ACEI) or bisoprolol (a b blocker) could prevent trastuzumab-related cardiotoxicity. 33 The primary outcome of trastuzumab-mediated left ventricular remodeling was not prevented by either agent. However, trastuzumab-associated declines in LVEF were slightly reduced by the agents compared with placebo. Therefore, further evaluation of promising cardioprotective agents in larger prospective trials is warranted before routine use. The ongoing SAFE-HEART trial is also investigating the safety of initiating or continuing HER2-targeted therapy in patients with asymptomatic, mildly reduced LVEF (range, 40%-49%; clinicaltrials.gov identifier NCT01904903).
An important question, which this study was not designed to answer, is whether the higher rates of treatment-induced cardiotoxicity and incomplete therapy observed in black patients is associated with inferior breast cancer outcomes. It has been known for several decades that black patients with breast cancer in the United States have higher population-based breast cancer mortality than white patients. 34, 35 This is not fully understood but may relate to differences in socioeconomic access to care, genetic and lifestyle factors, as well as a propensity to develop an aggressive breast cancer subtype (triple-negative breast cancer). When adjusted for age only because of the small number of events in an exploratory analysis, our data indeed indicated that black patients had significantly worse OS compared with white patients (results not shown). It must be noted that black patients were more likely to have higher stage disease and hormone receptornegative breast cancer. However, no significant associations were observed between the occurrence of cardiotoxicity and RFS/OS in our patient cohort, which may relate to the small sample size. Future studies with larger patient cohorts could help determine better the association between development of cardiotoxicity and breast cancer outcomes in black patients. 34 Although, to our knowledge, the current study is the largest to date investigating racial differences in cardiotoxicity and incomplete therapy in the setting of HER2-targeted therapy, it has some limitations. This was a retrospective study with a small sample size, although it was larger than some recent reports. 18, 19 There were insufficient data on certain baseline patient characteristics, such as body mass index at the time of diagnosis, the number of years since diagnosis of hypertension and diabetes, and whether these medical conditions were well or poorly controlled. Data on symptomatic cardiac dysfunction were not collected. The number of events (death and relapse) was small, and longer follow-up would be preferable to strengthen the associations reported. Another limitation is that transthoracic echocardiograms were used for most patients; these imaging studies are less precise and more operator-dependent than multiple-gated acquisition scans, although they are more readily available, less expensive, and are not associated with radiation exposure. 36 In summary, this study has demonstrated that the rate of cardiotoxicity is higher among black women and is highly concordant with receiving an incomplete course of HER2-targeted therapy. Enhanced surveillance for cardiotoxicity and, indeed, preventive measures may be warranted in this patient population. We propose that black patients who are receiving HER2-targeted treatment should be closely monitored for early signs and symptoms of cardiotoxicity. Early referral to cardiology and interventions with ACEI/ARB agents, b blockers, and diuretics may provide improved cardiac function that will allow for reinitiation of HER2-targeted therapy, although this needs to be further studied in clinical trials. The use of concurrent chemotherapy regimens that avoid anthracyclines has also become more common in recent years, and their use will likely minimize cardiotoxicity and maximize optimal therapy for patients who have HER2-positive breast cancer. 4, 37 Moving forward, clinical trials should aim to include more minority patients and, indeed, should have specific cohorts that enroll minorities to expand our knowledge of the safety and efficacy of breast cancer regimens in these cohorts. Finally, the evaluation of data from randomized controlled trials and larger patient cohorts also is required to confirm our study findings and evaluate predisposing factors for the development of cardiotoxicity, including genetic predisposition, and may provide a stronger rationale for a more intense surveillance approach in this at-risk populations. 
